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ABSTRACT: This manuscript describes the production of Molecularly Imprinted Polymer nanoparticles (nanoMIPs) for the 
cardiac biomarkers heart-fatty acid binding protein (H-FABP) and ST2 by solid-phase synthesis, and their use as synthetic 
antibodies in a multiplexed sensing platform. Analysis by Surface Plasmon Resonance (SPR) shows that the affinity of the 
nanoMIPs is similar to that of commercially available antibodies. The particles are coated onto the surface of thermocouples 
and inserted into 3D-printed flow cells of different multiplexed designs. We demonstrate it is possible to selectively detect 
both cardiac biomarkers within the physiologically relevant range. Furthermore, the developed sensor platform is the first 
example of a multiplex format of this thermal analysis technique which enables simultaneous measurements of two differ-
ent compounds with minimal cross selectivity. The format where three thermocouples are positioned in parallel exhibits 
the highest sensitivity, which is explained by modelling the heat flow distribution within the flow cell. This design is used 
in further experiments and proof-of-application of the sensor platform is provided by measuring spiked fetal bovine serum 
samples. Due to the high selectivity, short measurement time, and low-cost of this array format, it provides an interesting 
alternative to traditional immunoassays. The use of nanoMIPs enables a multi-marker strategy, which has the potential to 
contribute to sustainable healthcare by improving reliability of cardiac biomarker testing.
The onset of acute chest pain is one of the most common rea-
sons for emergency department attendance.1 Diagnostic cor-
nerstones for patients exhibiting these symptoms include clin-
ical assessment, performing an electrocardiogram (ECG), and 
measurements of cardiac biomarker levels.2 Early diagnosis of 
acute coronary syndrome (ACS), for which chest pain is one of 
the main symptoms, significantly impacts patient morbidity 
and mortality.3 Out of the patients with acute chest pain, an 
estimate of merely 20 % are suffering from ACS. Due to diffi-
culty in the reliable identification of these patients, hospital 
admission with biomarker measurements has been the stand-
ard protocol.4 In 2016, the European Society of Cardiology rec-
ommended 1-hour and 3-hour rule-out strategies for Acute 
Myocardial Infarction (AMI), which involved the use of highly 
sensitive cardiac troponin (hs-cTn) assays.5 Strategies that 
consider these assays include the Manchester ACS (MACS)6 
and Troponin-only (T-MACS)7, which have been able to 
highly accurately (sensitivity 99.1 %) determine the probabil-
ity that a patient will undergo a major adverse cardiac event 
within 30 days.8 The MACS rule incorporates high sensitivity 
troponin T (hs-TnT), heart fatty acid binding protein (H-
FABP), ECG findings and clinical data; whereas T-MACS ex-
cludes H-FABP as a variable. Reliability of these rule-out strat-
egies can be enhanced if, besides troponin, other biomarkers 
are considered, which could include H-FABP (as shown in 
MACS) and ST2. The first is a cytoplasmic protein of molecular 
weight 15 kDa with serum levels in healthy humans ranging 
between 0 – 2.8 ng/mL.9 Upon experiencing an ischemic epi-
sode, H-FABP is quickly released from the myocardial cells, 
whereas troponin levels gradually increase over the course of 
a few hours.10 Hoffman et al., reported that additional H-FABP 
measurements improve the diagnostic specificity of a NT-
proBNP assay to rule out acute heart failure.11 McCann et al., 
demonstrated that determination of H-FABP and troponin-T 
levels offer the best diagnostic sensitivity over all timepoints.12 
Soluble ST2 is a member of the interleukin receptor family and 
increases in serum levels have been reported to be propor-
tional to the severity of heart failure.13 The Framingham Heart 
Study showed that the soluble ST2 levels in plasma varied 
 
from 9 – 45 ng/mL, with significant differences reported de-
pending on age and gender.14 As increases in ST2 are not uni-
versal, they are less suitable as a prognostic marker, but can 
still offer valuable information when used in combination 
with other biomarkers.15 Ho et al., have suggested that soluble 
ST2 has a role in the prediction of cardiovascular outcome 
when a multi-marker strategy, including troponin and BNP, is 
considered.16 Therefore, there is high demand to develop as-
says for the simultaneous measurement of multiple cardiac bi-
omarkers in a fast, simple and low-cost manner to enhance the 
reliability of patient diagnosis. In this manuscript, we focus on 
H-FABP and ST2 and discuss a sensor platform for the simul-
taneous determination of these cardiac biomarkers by com-
bining Molecularly Imprinted Polymers (MIPs) as recognition 
elements alongside thermal detection. MIPs are formed via a 
process in which monomers and cross-linker self-assemble 
around the target molecule, according to the exposed func-
tionalities. The resulting polymerization process ‘freezes’ the 
monomers in place and effectively creates specific binding 
sites. In traditional MIP synthesis, the target molecule is re-
moved to empty these binding sites, which are then able to re-
bind the target molecule.17,18 However, this process suffers 
from serious disadvantages including the heterogeneous dis-
tribution of MIP binding sites, template leaching, and diffu-
sion limitation of binding. High affinity MIP nanoparticles 
(nanoMIPs) can be produced through a solid-phase approach, 
which involves polymerization around the template that is co-
valently attached to a solid support.19 These nanoMIPs exhibit 
good biocompatibility20 and possess superior thermal and 
chemical stability compared to their natural counterparts, 
while maintaining high affinity21. Due to the use of our spe-
cialist reactor19, it is possible to elute down the produced na-
noparticles at various temperatures and thereby pre-select na-
noMIPs according to their affinity instead of removing the 
template from the polymeric receptors. This process involves 
a step at low temperature during which unreacted monomers 
and low affinity nanoMIPs are removed, followed by a step at 
elevated temperature to collect solely nanoMIPs with high af-
finity. Therefore, it is possible to obtain nanoMIPs that exhibit 
superior affinity and a homogenous distribution of binding 
sites compared to traditional bulk microparticles.  
In previous research, we have demonstrated that nanoMIPs 
can be dip-coated onto thermocouples and used to detect bi-
omolecules in buffered solutions by monitoring the tempera-
ture of a liquid in a flow cell.22 This strategy is limited to mon-
itoring of a single compound and has not been applied to clin-
ical samples due to issues with matrix effects. Herein, we will 
describe the development of two novel high affinity nanoMIPs 
for H-FABP and ST2 that have not been reported in literature 
and demonstrate that we can measure these molecules at 
physiologically relevant concentrations using thermal analy-
sis. A novel flow cell design will be presented that enables ar-
ray formatting and implementation of an internal control, 
which has the potential for simultaneous biomarker measure-
ments. This new thermal sensor platform holds great promise 
for therapeutic and diagnostics due to its simplicity, low-cost, 
and high sensitivity and selectivity of the nanoMIPs.  
Experimental Section: Chemicals Phosphate buffered sa-
line (PBS) solutions were made using PBS tablets (Sigma, UK) 
and de-ionized water of resistivity not less than 18.2 MΩ cm. 
Fetal bovine serum (FBS) was purchased from Sigma (UK) and 
used without any modification. Heart fatty acid binding pro-
tein (H-FABP) was purchased from ATGen (US) and ST2 was 
purchased from Abcam (Cambridge, UK). Chemicals and 
equipment for the synthesis and analysis of the nanoMIPs are 
presented in Canfarotta et al.20a 
Synthesis of H-FABP and ST2 nanoMIPs Protocol was 
adapted from Canfarotta et al.20a Briefly, glass beads (diameter 
between 70 – 100 µm) were activated with 2 M NaOH and sub-
sequently functionalized with a silane group to obtain beads 
with free amine groups on the surface. The target proteins 
were immobilized onto the amine-derivatized glass beads via 
glutaraldehyde coupling. Immobilization of H-FABP and ST2 
was confirmed by monitoring colour changes with bicin-
chonic acid assay. NanoMIPs were prepared according to a 
proprietary modified version of the protocol described in Can-
farotta et al.20a, which involves radical polymerization of func-
tional and crosslinker monomers at room temperature for 2 h. 
After polymerization, the solid support was used to isolate the 
high-affinity nanoMIPs from the remaining monomers, oligo-
mers and low-affinity polymers. This was achieved by first us-
ing a low temperature elution followed by an elevated temper-
ature elution (~60 °C).19 
Size and Concentration Analysis of nanoMIPs The particle 
size was measured with a Zetasizer Nano (Nano-S) particle-
size analyzer (Malvern Instruments Ltd., UK) at 25 °C. Biacore 
analysis was performed on SIA Au SPR gold chips (GE 
Healthcare) that were modified with mercaptoundecaonic 
acid onto which nanoMIPs were coupled via EDC/NHS chem-
istry. Flow conditions were set at 30 µL/min and excess NHS 
esters were deactivated by injecting with 100 µL of ethanola-
mine hydrochloride (0.1 M) at 10 µL/min. Five different con-
centrations of the target protein (0.05 – 250 nM) in PBS were 
injected. A control channel functionalized with nanoMIPs 
produced for target trypsin using the same monomer and 
cross-linker composition was used as a negative control. The 
dissociation time was set at 5 min and the data was analyzed 
using BiaEvaluation software (v 4.1) to obtain Kd values. 
Thermal Measurements of nanoMIPs Sensors The MIP-
functionalized thermocouples were prepared according to the 
protocol from Canfarotta et al. as seen in the Supporting In-
formation (Figure S-1).22 Type K thermocouples (RS Compo-
nents, UK) were exposed to solutions of nanoMIPs in water for 
1 min, with an insertion and withdrawing rate of 5.1 cm/min. 
After drying (2 h), the functionalized thermocouples were in-
serted into flows cells fabricated in-house through 3D printing 
(Supporting Information S-2). These were produced on a 
FORM 2 stereolithography 3D-Printer (FormLabs, USA) using 
FORM 2 Clear Resin (GPCL04). The flow cells were subse-
quently coupled to a heat-transfer device as described by van 
Grinsven et al.23 The device was steered with LabView software 
that actively controls the temperature of the copper block (T1). 
A proportional-integral-derivative (PID) controller that is at-
tached a power resistor (22 Ω) regulated the feedback on the 
signal.24 In this work, the PID parameters were optimized 
through tuning experiments. These values were defined as 1: 
14: 0.3 and these were used throughout the experiments. In all 
sensing measurements presented within this manuscript, the 
temperature was kept constant at 37.00 ± 0.02 °C to mimic in-
vivo conditions. The thermocouples functionalized with nano-
MIPs are inserted into the liquid inside the flow cell 1.7 mm 
above the sensor surface of the chip. This temperature is de-
fined as T2 and measurements take place every second. In all 
 
measurements, the flow cells were filled with a solution of PBS 
and were left for 45 min to ensure stabilization of the baseline 
temperature signal measured by the functionalized thermo-
couple. Solutions (3 mL) of the target biomarker (H-FABP 1.5 
– 75 ng/mL; ST2 3.15 – 315 ng/mL) were prepared in PBS or in 
FBS (ST2 63 – 1575 ng/mL) prior to experiments and stored at 
4 °C until required. Each biomarker injection was performed 
at 250 µL/min for 12 min using an automated NE500 program-
mable syringe pump (ProSense, Oosterhout, the Nether-
lands). Following each sample addition, the system was al-
lowed to stabilize for 30 min prior to the next injection. The 
thermal resistance (Rth) was determined throughout the 
whole measurement by dividing the temperature gradient (T1 
– T2) over the power required to keep the heat sink at the set 
temperature.22 The Rth alongside the standard deviation of 
each thermocouple was calculated using the average of 600 
data points before the beginning of each injection. This data 
was used to construct standard dose-response curves, from 
which the Limits of Detection (LoD) were calculated using the 
three sigma method in the linear range of the sensor. To es-
tablish the selectivity of the sensor in the single flow cells, 
measurements were performed with additions of another pro-
tein (BSA). In both the dual and triple cell systems an un-func-
tionalized thermocouple was placed in the cell alongside the 
functionalized thermocouple to act as a control. To determine 
the selectivity in the triple thermocouple set-up, a thermocou-
ple functionalized with the alternative biomarker nanoMIPs 
was used. 
Modelling of Heat Flow through Flow Cell Designs Com-
putational fluid dynamic (CFD) modelling was undertaken us-
ing Ansys Fluent V18.1 to give additional insight into the flow 
of heat within the cells. This was performed for both the single 
and triple thermocouple designs. Transient simulations were 
performed using a time-step of 0.5 s, which was selected fol-
lowing a time-step independence study. Mesh densities were 
optimized via a grid independence study: 174,077 cells for the 
single thermocouple design, 380,946 cells for the triple ther-
mocouple design. Approximately double the number of cells 
were required for the triple thermocouple design primarily 
due to the need for finer meshing in the regions of close prox-
imity. The boundary conditions were defined as follows: 1) 
Heat source, bottom surface of fluid domain was defined as a 
copper block with a constant temperature of 37 °C located 5 
mm from the fluid domain. 2) Heat sink, top surface of fluid 
domain was defined as the heat lost through a 1.3 mm poly-L-
lactic acid (PLLA) wall via convection to the environment at a 
bulk air temperature of 20 °C, with a film heat transfer coeffi-
cient of 25 Wm-2K-1. 3) All other surfaces were defined as adi-
abatic. Standard settings for modelling free convection in Flu-
ent were used, as outlined in the Fluent V18.1 user guide. This 
included the use of the Boussinesq approximation, which was 
suitable in this case due to the small temperature differences 
in the flow cell (initial fluid temperature of 20 °C, surround-
ings of 20 °C and heat source of 37 °C). The fluid was modelled 
as pure water. Each simulation was run for a total of 600 time 
steps, giving 300 s of simulation data per case, and each 
achieved an approximate steady state as indicated by the lev-
elling off of temperature and velocity fields. Solving each 
model took approximately 3 h, performed on a Dell OptiPlex 
7060, with an Intel i5-8500 CPU (6 cores) and 16 gb of RAM. 
Velocity and temperature fields were exported from the simu-
lation for post processing in the Ansys CFD-POST application. 
Results and Discussion: Production and Charactization 
of nanoMIPs The synthesized nanoMIPs were characterized 
based on their size and affinity for their target biomarkers. The 
hydrodynamic diameter of the synthesized nanoMIPs at 25 °C 
in distilled water was 280 ± 18 nm for the ST2 nanoMIPs and 
195 ± 4 nm for the H-FABP nanoMIPs. SPR analysis (Support-
ing Information S-3) revealed that a Kd value of 14 nM was ob-
tained for the ST2 nanoMIPs whereas for the H-FABP nano-
MIPs the Kd was estimated at 4 nM.  
Thermal Experiments with nanoMIPs Functionalized 
Thermocouples Dip-coating was used to functionalize nano-
MIPs for ST2 and H-FABP onto the thermocouples. Subse-
quently, these functionalized thermocouples were inserted 
into a single flow cell (Supporting Information S-2 A) which 
has been previously reported in literature and can measure 
one thermocouple at a time. The thermocouples were exposed 
to PBS solutions with increasing concentrations of the target 
molecule. In all cases, the temperature of the heat sink (T1) 
was strictly controlled to 37.00 ± 0.02 °C whereas T2 was solely 
monitored. Previous research has demonstrated that binding 
of the target to the imprints in the nanoMIPs increases the re-
sistance at the solid-liquid interface, which leads to lower 
temperatures of T2 being recorded by the thermocouple and 
thus higher Rth values.22 Results depicting the measured tem-
perature over time for the ST2 functionalized thermocouple 
and H-FABP functionalized thermocouple are presented in 
Supporting Information (S-4 B and C respectively). These fig-
ures clearly demonstrate a decrease in the temperature upon 
increasing the concentration of the appropriate biomarker 
due to binding of the protein to the polymer recognition layer. 
A similar response was observed for both cardiac biomarkers; 
whereas, upon the addition of a different protein (BSA, Sup-
porting Information S-5 B and C) there was no significant 
change in the in the measured Rth values. This provided evi-
dence toward the specificity of the nanoMIPs recognition ele-
ments. After providing proof-of-principle, other flow cell de-
signs were explored in order to facilitate multiplexing and to 
minimize the influence of external parameters. An initial ex-
periment consisted of connecting two single flow cells to-
gether in series and comparing the response of an ST2 func-
tionalized thermocouple to that of a blank (non-functional-
ized) thermocouple (Supporting Information S-6). These re-
sults demonstrated decreases in T2, corresponding to the func-
tionalized thermocouple, whereas the temperature of the 
blank thermocouple remained unaffected. The main draw-
back of putting two flow cells in series is the requirement for 
double the sample size, which is not feasible in a clinical set-
ting. Therefore, the initial design was adapted and novel flow 
cells were 3D printed. In the first set of flow cells, one addi-
tional inlet was added directly opposite the initial thermocou-
ple inlet. This allowed for the simultaneous measurement of 
two thermocouples in the same flow cell. Figure 1 shows the 
raw data plots of Rth over time for additions of ST2 to a flow 
cell containing an ST2 functionalized thermocouple and an 
un-functionalized thermocouple (figure 1B). In PBS, the Rth 
value stabilized at 3.69 ± 0.04 °C/W for the blank thermocou-
ple and 4.36 ± 0.05 °C/W for the functionalized thermocouple. 
These differences in stabilized Rth values can be affected by 
different variables including increased resistance due to the 
presence of particles on the thermocouple surface. Significant 
changes in the Rth, with respect to the baseline stabilization, 
were determined with concentrations of 6.3 ng/mL and 
higher, with a dynamic range of the sensor between 6.3 ng/mL 
 
and 63 ng/mL. Upon the addition of 6.3 ng/mL an increase in 
the absolute Rth was observed on the functionalized thermo-
couple from its baseline of 4.36 ± 0.05 °C/W to 4.49 ± 0.05 
°C/W. This corresponded to a 3.0 ± 1.6 % increase in the Rth 
signal. The increase in the Rth continued for the additions of 
ST2 up until the final addition of 315 ng/mL where the Rth had 
increased to 4.75 ± 0.05 °C/W, corresponding in an 8.9 ± 1.6 % 
increase from the baseline level. These results were plotted in 
the form of a dose-response curve (Figure 1 D, red circles), 
which was used to calculate a limit of detection (LoD) of 20 ± 
4 ng/mL which corresponded to 312 ± 66 pM. Therefore, in 
addition to the simultaneous measurement of a blank thermo-
couple to improve reliability, this system showed a ten-fold 
increase in the sensitivity compared to the 5 nM LoD obtained 
in previous work on protein detection using nanoMIPs.22 We 
can attribute this improvement in LoD to the enhanced affin-
ity of the nanoMIPs, in addition to the novel design of the flow 
cells since the computational modelling shows it improves 
mixing of the liquid and minimizes noise of the thermocouple 
signal. In further experiments, it was studied whether this 
technique could be extended to the biomarker H-FABP. 
 
Fig-
ure 1. A) Schematic of the dual thermocouple flow cell used. B) Raw data HTM plot of the Rth over time for the addition of ST2 
(3.15 – 315 ng/mL) in PBS to a dual thermocouple set-up with one thermocouple functionalized with ST2 nanoMIPs (red) and one 
un-functionalized thermocouple (black). C) Raw data HTM plot of the Rth over time for the addition of H-FABP (1.5 – 75 ng/mL) 
in PBS to a dual thermocouple set-up with one thermocouple functionalized with H-FABP nanoMIPs (blue) and one un-function-
alized thermocouple (black). D) Dose-response curve for the addition of ST2 (3.15 – 315 ng/mL) in PBS to an ST2 nanoMIP func-
tionalized thermocouple (red circles) and H-FABP (1.5 – 75 ng/mL) in PBS to an H-FABP nanoMIP functionalized thermocouple 
(blue squares) in the dual thermocouple set-up.
Figure 1C exhibits the raw data Rth response for a dual thermo-
couple flow cell in which one thermocouple is functionalized 
with H-FABP nanoMIPs (blue) and the other thermocouple is 
un-functionalized. This once again clearly demonstrated an 
increase in the measured Rth for the functionalized thermo-
couple upon the addition of target biomarker. In PBS, the Rth 
values stabilized at 2.88 ± 0.04 °C/W for the un-functionalized 
thermocouple and at 3.26 ± 0.03 °C/W for the H-FABP func-
tionalized thermocouple. Significant changes in the measured 
Rth for the H-FABP functionalized thermocouple were ob-
served upon the addition of 1.5 ng/mL with a working range 
up to 75 ng/mL. Upon the addition of 1.5 ng/mL of H-FABP, 
the Rth measured at the functionalized thermocouple in-
creased to 3.34 ± 0.03 °C/W, corresponding to an increase of 
2.5 ± 1 .3% from the baseline value. The increase in Rth contin-
ued up to the last injection of 75 ng/mL where it reached 3.70 
± 0.04 °C/W, corresponding to an increase of 13.5 ± 1.5 %. Once 
again this allowed for the conversion into a dose-response 
curve and elucidation of a LoD of 4.18 ± 0.73 ng/mL.  
 
To improve the performance of the sensing platform the flow 
cell design was further modified to incorporate an additional 
thermocouple. This was done by elongating the inner cham-
ber of the flow cell (Supporting Information S-2D), which in-
creased the cell volume by 20 µL. The extension of the inner 
chamber permitted the staggering of thermocouple insertion 
points and allowed for the now parallel thermocouples to span 
the entire width of the flow cell chamber; meaning it is possi-
ble to control the insertion depth of each thermocouple. The 
addition of an extra thermocouple allowed for another control 
to be added to the system; by functionalizing one thermocou-
ple with nanoMIPs for the biomarker not being used as a tar-
get. The results of this experiment, where the first thermocou-
ple was functionalized with H-FABP, the second with the tar-
get nanoMIPs ST2 and the third thermocouple was left un-
functionalized are presented in Figure 2. 
 
Fig-
ure 2. A) Schematic of the triple thermocouple flow cell used. B) Raw data HTM plot of the Rth over time for the addition of ST2 
(3.15 – 315 ng/mL) in PBS to a triple thermocouple set-up with one thermocouple functionalized with ST2 nanoMIPs (red), one 
functionalized with H-FABP nanoMIPs (blue) and one un-functionalized thermocouple (black). C) Dose-response curve for the 
addition of ST2 (3.15 – 315 ng/mL) in PBS to a thermocouple functionalized with ST2 nanoMIPs in a triple thermocouple set-up. 
D) Plot showing the change in Rth value versus the concentration of ST2 injected into the flow cell for each thermocouple (red 
circles = ST2, blue square = H-FABP and green triangles = Blank.
In PBS, the Rth values stabilized at 3.38 ± 0.03 °C/W for the ST2 
nanoMIP functionalized thermocouple, 2.33 ± 0.02 °C/W for 
the H-FABP nanoMIP functionalized thermocouple and 1.49 ± 
0.02 °C/W for the un-functionalized thermocouple. The func-
tionalized thermocouples were expected to have a larger base-
line stabilization Rth value then the un-functionalized thermo-
couple due to the presence of the insulating plastic nanopar-
ticles on their surface. However, the major reason for varia-
tions in thermocouple stabilization values is the variance in 
manufacturing. This variance is shown in Supporting Infor-
mation S-7B. Although the absolute temperature values meas-
ured were shown to vary by up to 1.5 °C, once the stabilization 
value was reached the accuracy of this measurement was 
maintained with a standard deviation of ± 0.01 °C calculated 
over 600 data points. The position of the thermocouple inside 
the flow cells, meaning whether the thermocouple is in the 
front, middle or back of the cell, has minimal effect on the 
measurement as seen in Supporting Information S-7C. This 
showed only small variations in measured temperature when 
the thermocouples were shifted to a different position and a 
temperature gradient applied.  
 
Upon the addition of 6.3 ng/mL of ST2, the Rth value measured 
at the ST2 nanoMIP functionalized thermocouple increased to 
3.54 ± 0.04 °C/W, corresponding to an increase of 4.7 ± 1.5 % 
from the baseline value. This increase in the Rth continued up 
until the last injection of 315 ng/mL where the Rth reached 3.93 
± 0.04 °C/W, corresponding to an increase of 16.3 ± 1.5 %.  The 
percentage increase observed for the triple cell system was al-
most double that observed in the double cell for the same con-
centration range of ST2. The raw data was converted into a 
dose-response curve, figure 3C, which allowed the elucidation 
of an LoD of 8.79 ± 0.79 ng/mL or 140 ± 13 pM. Therefore, the 
LoD had exhibited a decrease of over 50 %. The improvements 
observed when switching from the single/double cell design 
to the triple cell were explained through computational mod-
elling (Supporting Information S7). The triple cell reaches a 
steady temperature faster than the single cell. In this configu-
ration it was seen that the central thermocouple is consist-
ently 0.6 °C lower than the other two thermocouples. The av-
erage velocity magnitude was observed to be lower in the tri-
ple cell which is seen in the reduced noise values. This is ex-
plained by the smaller aspect ratio (height/hydraulic diame-
ter) in the three thermocouple system; where this suppressed 
the natural convection leading to a lower velocity magnitude 
and more stable signal. A comparison of the LoD’s achieved in 
literature and this work are presented in Table 1. The other 
sensing methodologies reported showed LoD’s an order of 
magnitude lower than this report; however, this work pre-
sented key advantages such as the multiplexing, greatly re-
duced costs and ease of sensor preparation whilst still provid-
ing analyte detection in the clinically relevant concentration 
ranges. The dip-coating method, although simple, can be im-
proved substantially in the future which would be expected to 
further enhance sensor performance. 
Table 1. Comparison table for the published methods of detection for H-FABP and ST2 biomarkers. 
Biomarker Recognition  
Element 
Read-Out Method Format LoD 
(ng/mL) 
Ref. 
H-FABPa AB’sb Capacitive Single 0.836 25 
H-FABPa AB’sb/QD’sc Fluorescence Single 0.221 26 
H-FABPa AB’sb ELISAd Single 0.3 27 
ST2 AB’sb ELISAd Single 1.3 28 
H-FABPa nanoMIPs Thermal Multiplex 4.18 This Work 
ST2 nanoMIPs Thermal Multiplex 8.79 This Work 




ure 3. A) Schematic of the triple thermocouple flow cell used. B) Raw data HTM plot of the Rth over time for the addition of ST2 
(63 – 1575 ng/mL) in FBS to a triple thermocouple set-up with one thermocouple functionalized with ST2 nanoMIPs (red), one 
functionalized with H-FABP nanoMIPs (blue) and one un-functionalized thermocouple (black). C)  Plot of the Rth % change for 
the addition of ST2 (63 – 1575 ng/mL) in FBS to a triple thermocouple set-up with one thermocouple functionalized with ST2 
nanoMIPs (red circles), one functionalized with H-FABP nanoMIPs (blue squares) and one un-functionalized thermocouple (green 
triangles). 
 
To provide a proof-of-application, an experiment was per-
formed injecting fetal bovine serum (FBS) that was spiked 
with ST2 (63 ng/mL – 1575 ng/mL), Figure 3. In FBS, the Rth 
stabilized at 2.69 ± 0.04 °C/W for the ST2 nanoMIP func-
tionalized thermocouple, 3.39 ± 0.04 °C/W for the H-FABP 
functionalized thermocouple and 2.45 ± 0.03 °C/W for the 
un-functionalized thermocouple. There was an observed 
increase in the noise on the raw data signals and the system 
takes noticeably longer to reach stabilization due to the 
more complex nature of the matrix. This included non-spe-
cific binding of proteins to the thermocouples and nano-
MIPs. Upon the addition of 63 ng/mL ST2 there is a larger 
increase in the measured Rth for the ST2 functionalized 
thermocouple to 2.89 ± 0.03 °C/W, corresponding to a 7.4 
± 1.8 % increase in the signal. This value is approximately 
50 % lower than the increase of 1± 1.5 % observed in the PBS 
medium. The Rth measured at the ST2 nanoMIP function-
alized thermocouple increased to a maximum for the addi-
tion of 315 ng/mL at a value of 3.01 ± 0.04 °C/W which cor-
responded to an increase of 11.9 ± 2.1 %. The increase in Rth 
measured at the ST2 nanoMIP functionalized thermocou-
ple was five times greater than at either of the other ther-
mocouples present, Figure 3C, showing the sensing plat-
form had good selectivity for the target biomarker in FBS. 
This demonstrates the possibility for this type of sensing 
platform to act as a traffic light system for a death predic-
tion cut-off points as reported by Pascual-Figal et al. 29 
Conclusions: MIP nanoparticles (size ranging from ~200-280 
nm) for ST2 and H-FABP as target molecules were prepared 
according to a solid phase approach. This is the first report of 
nanoMIPs for these cardiac biomarkers in literature, with de-
termined Kd values (4-14 nM) comparable to that of commer-
cially available antibodies. Thermocouples were functional-
ized with nanoMIPs via dip coating and inserted into flow cells 
that were coupled to a home-made thermal measurement de-
vice.  Addition of buffered solutions containing the relevant 
cardiac biomarkers resulted in an increase of the thermal re-
sistance at the solid-liquid interface of the functionalised ther-
mocouple. This resulted in a lower temperature recorded in 
the fluid. Dose-response curves were constructed to correlate 
the biomarker concentration to the thermal resistance. Differ-
ent flow cell designs were explored, with computational mod-
 
elling providing insight into the optimal configuration by de-
termining the heat distribution through the system. The de-
veloped sensor platform was capable to simultaneously meas-
ure ST2 and H-FABP, with minimal cross selectivity between 
the two markers. It was possible to measure both in buffered 
solutions and spiked serum solutions within the psychologi-
cally relevant range, demonstrating proof-of-application of 
the technology.  The use of nanoMIPs combined with thermal 
read-out enables a multimarker strategy which could have 
high potential for sustainable healthcare due to its low-cost, 
straightforward operation, and ability to tailor the sensor to-
wards the required target. 
 
Supporting Information 
Supporting Information available:  The following files are 
available free of charge.  nanoMIPscardiacbiomarkerdetec-
tion_20092019_SupportingInformation. The Supporting 
Information contains the details of the functionalisation 
procedure, SEM of a functionalised thermocouple, sche-
matic of the flow cells used, SPR analysis of the nanoMIPs, 
and HTM measurements done on a single cell flow cell de-
sign. Further information on the cell set ups, the influence 
of the position of the thermocouple and computational 
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